DEF: Rafael Holdings Sets 2026 Annual Meeting Agenda

Rafael Holdings, Inc. announces its 2026 Annual Meeting of Stockholders to elect directors, ratify auditors, and approve an increase in its equity incentive plan shares.

Summary

• The Annual Meeting of Stockholders will be held on Thursday, January 8, 2026, at 11:30 a.m. local time, at the company's offices in Newark, New Jersey.
• The record date for stockholders entitled to vote at the Annual Meeting is November 11, 2025.
• Stockholders will vote on three key proposals: electing six directors for a one-year term, ratifying CohnReznick LLP as the independent registered public accounting firm for the Fiscal Year ending July 31, 2026, and approving an amendment to the 2021 Equity Incentive Plan to increase the number of shares of Class B Common Stock available for awards by 1,000,000, bringing the total to 4,365,795 shares.
• As of the record date, 51,762,801 shares were issued and outstanding and entitled to vote, consisting of 787,163 shares of Class A Common Stock (three votes per share) and 50,975,638 shares of Class B Common Stock (one-tenth of one vote per share).
• The company qualifies as a 'controlled company' but does not rely on the associated NYSE exemptions, maintaining a majority of independent directors and fully independent Audit, Compensation, and Corporate Governance Committees.
• Net loss for Fiscal 2025 was $30,643,000, a significant improvement from $65,003,000 in Fiscal 2024, but higher than $2,215,000 in Fiscal 2023.
• Total Shareholder Return (TSR) based on a hypothetical $100 investment beginning July 31, 2022, was $84.86 for Fiscal 2025, $73.76 for Fiscal 2024, and $99.01 for Fiscal 2023.
• Extensive related party transactions were disclosed, including services provided by IDT Corporation (controlled by Howard S. Jonas) and services provided to Cornerstone Pharmaceuticals, Inc. (67% owned by the company, with Howard S. Jonas also holding an interest and serving as Chairman).

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. While the company demonstrates good corporate governance and a reduction in net loss, the continued substantial losses, declining Total Shareholder Return, and executive turnover present concerns. The recent capital raise, largely backstopped by the controlling shareholder, suggests a need for funding. The proposed increase in the equity incentive plan is positive for talent retention but also implies potential dilution.

Positives

• The company demonstrates strong corporate governance by not relying on 'controlled company' exemptions, maintaining a majority of independent directors and fully independent Audit, Compensation, and Corporate Governance Committees.
• Net loss decreased significantly from $65,003,000 in Fiscal 2024 to $30,643,000 in Fiscal 2025, indicating an improvement in financial performance.
• The proposed amendment to the 2021 Equity Incentive Plan aims to provide a sufficient reserve of shares for future grants, which is essential for attracting and retaining key employees, directors, and consultants.
• The acquisition of Cyclo Therapeutics, Inc. in March 2025 is a strategic move that focuses the company's activities and may lead to positive outcomes in the near to medium term.

Negatives

• The company continues to report substantial net losses, totaling $30,643,000 in Fiscal 2025.
• Total Shareholder Return has declined for two consecutive fiscal years, with a hypothetical $100 investment yielding $84.86 by July 31, 2025.
• Significant executive turnover occurred in Fiscal 2025, with William Conkling resigning as Chief Executive Officer and John Goldberg resigning as Chief Medical Officer.
• A Form 4 for William Conkling was filed late on April 24, 2025, indicating a lapse in beneficial ownership reporting compliance.

Risks

• Broker non-votes on non-routine proposals (director election, equity plan amendment) could impact the approval of these items, as brokers lack discretionary authority to vote without instructions from beneficial owners.
• Extensive related party transactions with entities controlled by Howard S. Jonas or his family (IDT Corporation, Cornerstone Pharmaceuticals, Inc., Nina Medical Ltd.) could present actual or perceived conflicts of interest.
• The proposed increase of 1,000,000 shares for the 2021 Equity Incentive Plan could lead to dilution for existing shareholders.
• The company's ability to attract and retain key employees, directors, and consultants is crucial for long-term success, and failure to do so could adversely impact operations.
• The market price of Class B Common Stock, which affects the value of equity compensation and Total Shareholder Return, has shown volatility, posing a risk to shareholder value and executive incentives.
• Curtailing activities of certain operating units, as mentioned in Fiscal 2025, may indicate challenges or a narrowing of strategic focus, which could impact future growth opportunities.

Future Outlook

The company intends to continue leveraging its 2021 Equity Incentive Plan to attract and retain key employees, directors, and consultants, with a proposed increase of 1,000,000 shares for future awards. The Compensation Committee will regularly review non-employee director compensation practices. The company's management commentary suggests a continued focus on seeking out opportunities and lead product candidates, building on the strategic acquisition of Cyclo Therapeutics, Inc. and curtailing other operating units to achieve significant positive outcomes in the near to medium term.

Management Comments

• "The Compensation Committee believes that our non-employee director compensation is fair and appropriate in light of the responsibilities and obligations of our non-employee directors."
• "The Board of Directors believes that the proposed amendment to increase the number of shares of Class B Common Stock available for the grant of awards thereunder by 1,000,000... is necessary in order to provide the Company with a sufficient reserve of shares... essential to the Company’s long-term success."
• "During Fiscal 2025, the Company consummated the acquisition of Cyclo while curtailing activities of certain other operating units, and the market price of our Class B Common Stock, reflected, to some degree, the focus and prospect for a significant positive outcome in the near to medium term with the resultant positive impact on the value of the equity portion of executive compensation for both our Chief Executive Officer and the other Named Executive Officers."

Industry Context

The company operates within the healthcare, pharmaceutical, and biotechnology sectors, as evidenced by its investments in Cornerstone Pharmaceuticals, Inc., the acquisition of Cyclo Therapeutics, Inc., and the medical and scientific expertise of its board members. The emphasis on attracting and retaining talent through equity incentives is a common and critical practice in the highly competitive and innovation-driven biotech industry. The company's strategic focus on lead product candidates and the impact of market price on executive compensation align with typical industry dynamics where stock performance is often tied to pipeline progress and strategic M&A activities.

Comparison to Industry Standards

• **Corporate Governance**: Despite qualifying as a 'controlled company,' the company voluntarily adheres to stricter NYSE independence requirements for its board and key committees (Audit, Compensation, Corporate Governance), which is a higher standard than the minimum required for controlled companies.
• **Director Expertise**: The board includes practicing medical oncologists (Dr. Mark N. Stein, Dr. Michael J. Weiss) with direct experience in cancer treatments, clinical trials, and pharmaceutical investments, providing highly relevant expertise for a company with significant pharmaceutical holdings like Cornerstone Pharmaceuticals and Cyclo Therapeutics. Markus W. Sieger also brings extensive healthcare industry experience from his role at Polpharma Group.
• **Executive Compensation**: The compensation structure, which combines cash and equity awards, is a standard industry practice designed to align executive interests with shareholder value. However, the 'Pay vs. Performance' analysis reveals a decline in Total Shareholder Return over two fiscal years while 'Compensation Actually Paid' to executives has fluctuated, which may warrant closer scrutiny compared to industry peers who might link compensation more directly to positive shareholder returns.

Management Changes

Corporate Governance

Related Party Transactions

• Howard S. Jonas beneficially owns a controlling interest in the company and IDT Corporation. Trusts for his children also own controlling interests in both entities.
• IDT Corporation provides administrative and legal services to the company under a Transition Services Agreement (TSA). IDT billed the company $275,323 in Fiscal 2025. As of July 31, 2025, the company owed IDT $59,460.
• IDT Corporation leased approximately 3,600 square feet of office space from the company in Jerusalem, Israel. During Fiscal 2025, IDT paid the company $370,000 for office rent incurred during Fiscal 2025 and previous years. As of July 31, 2025, IDT owed the company $92,725 for office rent and parking.
• Howard S. Jonas, as the Standby Purchaser, and certain parties related to him and his family, purchased 16,400,770 shares of Class B Common Stock (Backstop Securities) at $1.28 per share for approximately $21 million in connection with the company's Rights Offering.
• The company beneficially owns 67% of the outstanding capital stock of Cornerstone Pharmaceuticals, Inc. Howard S. Jonas and David Polinsky also own an interest in Cornerstone Pharma, and Howard S. Jonas serves as its Chairman of the Board.
• The company provided Cornerstone Pharma with administrative, finance, accounting, tax, and legal services, billing $200,000 in Fiscal 2025. As of July 31, 2025, Cornerstone owed the company $200,000.
• Chai Inspiration Ventures LLC, a limited liability company owned by various members of Howard S. Jonas's family, owns approximately 20% of the issued and outstanding Seed Preferred Shares and a warrant in Nina Medical Ltd. The company invested $500,000 in Nina Medical Ltd. on September 29, 2025.
• Sam Beyda, Howard Jonas's son-in-law, received a salary and bonus of $175,000 in Fiscal 2025 and a grant of 15,000 restricted shares of Class B Common Stock (later forfeited) while serving as Chief Executive Officer and a Director of Day Three Labs, Inc.

Stakeholder Impact

• **Shareholders**: Face potential dilution from the proposed increase in the equity incentive plan shares. The extensive related party transactions, while disclosed, could raise concerns about potential conflicts of interest and their impact on shareholder value. The declining Total Shareholder Return over the past two fiscal years directly impacts shareholder wealth.
• **Employees/Management**: The proposed increase in the equity incentive plan is designed to attract and retain key talent, which could benefit employees through equity awards. Executive compensation packages, including severance and vesting terms, are clearly defined. Changes in executive leadership (CEO, CMO) could influence company direction and employee morale.
• **Creditors/Suppliers**: The company's ongoing net losses, despite a reduction in Fiscal 2025, may be a concern for creditors. Financial obligations and receivables related to IDT Corporation, a related party, are part of the company's financial landscape.
• **Customers**: This proxy statement does not directly address customer impact. However, strategic moves like the Cyclo acquisition and focus on lead product candidates could eventually influence future product offerings and market presence.

Next Steps

• Stockholders are to vote on the election of six directors, the ratification of CohnReznick LLP as the independent auditor, and the approval of an amendment to the 2021 Equity Incentive Plan at the Annual Meeting on January 8, 2026.
• The Board of Directors may appoint an ex-officio member following the Annual Meeting.
• The Compensation Committee will periodically review non-employee director compensation practices.
• Stockholders wishing to present proposals for inclusion in the company's proxy materials for the 2027 annual meeting must submit them by July 31, 2026.
• Stockholder proposals submitted outside Rule 14a-8 for the 2027 annual meeting must be received by October 15, 2026.
• Stockholders intending to solicit proxies for director nominees must provide notice by November 11, 2026, to comply with universal proxy rules.

Key Dates

Recommendation

The company demonstrates a commitment to strong corporate governance by not leveraging its 'controlled company' status for board independence exemptions. The reduction in net loss from Fiscal 2024 to Fiscal 2025 is a positive sign, and the strategic acquisition of Cyclo Therapeutics indicates a focused direction. However, the company continues to incur substantial net losses, and the Total Shareholder Return has been negative over the past two fiscal years. Executive turnover, while addressed, adds a layer of uncertainty. The extensive related party transactions, though disclosed and approved, warrant careful monitoring for potential conflicts of interest. The proposed increase in the equity incentive plan is necessary for talent retention but also implies future dilution. Given these mixed signals, a 'Hold' recommendation is appropriate for investors to observe further operational and financial developments.

Keywords

Rafael Holdings, Proxy Statement, Corporate Governance, Equity Incentive Plan, Director Election, Auditor Ratification, Executive Compensation, Related Party Transactions, Class B Common Stock, NYSE, Financial Reporting, Risk Management, Shareholder Meeting, Cyclo Therapeutics, Biotechnology, Pharmaceuticals